Q2 2025 Management View William J. Sibold, CEO, highlighted a "productive last few months" focused on driving the launch and building for the future, noting, "Rezdiffra’s quarterly run rate now ...

Las Vegas(KLAS)-TV Personality, Peter Madrigal, has launched ‘Reality Network’ providing a one stop shop for all things ...

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

Madrigal (MDGL) delivered earnings and revenue surprises of +45.40% and +32.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility <li /> $350 million initial term ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...